07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

Acrux management update

Acrux Ltd. (ASX:ACR), Melbourne, Australia   Business: Drug delivery   Hired: Michael Kotsanis, chief commercial officer of Synthon B.V. , as CEO and managing director, effective Nov. 3; he will succeed Ross Dobinson, who will...
08:00 , Feb 18, 2013 |  BC Week In Review  |  Clinical News

Androxal enclomiphene: Completed Phase III enrollment

Repros completed enrollment of 500 patients in the 6-month, open-label, dose-escalation, U.S. Phase III ZA-300 trial comparing once-daily, oral 12.5 mg Androxal vs. topical Axiron testosterone. The company said the trial is part of FDA's...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Clinical News

Axiron testosterone regulatory update

Acrux said Australia's Therapeutic Goods Administration (TGA) approved Axiron testosterone as an androgen replacement therapy for testosterone deficiency in men. Additionally, the Pharmaceutical Benefits Advisory Committee (PBAC) approved Axiron for reimbursement on the Pharmaceutical Benefits...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Clinical News

EvaMist regulatory update

FDA updated the label of EvaMist estradiol metered-dose transdermal spray to include a boxed warning that breast budding, breast masses and gynecomastia have been reported in children following unintentional secondary exposure to the drug. Acrux...
07:00 , Jul 4, 2011 |  BioCentury  |  Finance

3Q Financial Markets Preview: Hoping the rally has legs

Buysiders expect biotech may be able to continue to outperform the broader markets, despite a retreat from spring highs. In particular, they see two bright spots for the sector: selective gains on a full calendar...
07:00 , Jun 6, 2011 |  BioCentury  |  Finance

Prima targets NASDAQ

Prima targets NASDAQ Australia's Prima BioMed Ltd. (ASX:PRR) hopes to capitalize on the substantial interest in fellow cancer immunotherapy play Dendreon Corp. (NASDAQ:DNDN) by listing on NASDAQ. CEO Martin Rogers said the company is awaiting...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Company News

Acrux, Eli Lilly sales and marketing update

Eli Lilly launched Axiron testosterone in the U.S. as replacement therapy in men for conditions associated with a deficiency or absence of testosterone, including primary and hypogonadotropic hypogonadism. Eli Lilly has worldwide rights to the...
08:00 , Jan 10, 2011 |  BioCentury  |  Finance

Buyside View XIX: Commercial Risk

Michael Flanagan Senior Writer  BioCentury's 19th Annual Buyside View finds money managers entering 2011 cautiously optimistic about biotech's prospects, particularly as some of the high-profile compounds have already reported some data, lowering risk. Amidst the...
08:00 , Jan 3, 2011 |  BioCentury  |  Finance

Trickle-down effect

Although companies in the $1-$1.9 billion market cap range were the big winners for 2010 with a 28% gain, last quarter saw gains migrate into lower rungs of the market cap ladder. Small caps with...
08:00 , Dec 6, 2010 |  BC Week In Review  |  Clinical News

Axiron testosterone regulatory update

FDA approved an NDA from Acrux for Axiron testosterone as replacement therapy in men for conditions associated with a deficiency or absence of testosterone, including primary and hypogonadotropic hypogonadism. Eli Lilly, which has worldwide rights...